Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an update.
Rhythm Biosciences Ltd has successfully reinstated NATA accreditation for its geneType cancer risk assessment portfolio, following the acquisition of Genetype assets from Genetic Technologies Ltd. This milestone is pivotal for the company’s ColoSTAT® commercialisation strategy, allowing it to progress as an in-house in vitro diagnostic (IVD) and generate real-world data, essential for its global commercialization efforts.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden by partnering with global entities for the commercialization and distribution of its solutions.
Average Trading Volume: 245,098
Technical Sentiment Signal: Sell
Current Market Cap: A$18M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.